Myogen starts phase 3 trial of ambrisentan in pulmonary hypertension

By Lisa Kerner

Charlotte, N.C., Sept. 7 - Myogen, Inc. began Aries-3 (AMB-323), its phase 3 long-term, open-label safety and efficacy study of ambrisentan in 200 patients with pulmonary hypertension characterized by severe constriction of the blood vessels in the lungs.

The primary endpoint of the trial is the change from baseline in six-minute walk distance (6MWD) at week 24.

Ambrisentan once-daily oral therapy has demonstrated a statistically significant improvement in 6MWD in prior clinical trials in patients with pulmonary arterial hypertension.

Myogen is a Denver-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.